MX2021003764A - Determinacion de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia. - Google Patents

Determinacion de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia.

Info

Publication number
MX2021003764A
MX2021003764A MX2021003764A MX2021003764A MX2021003764A MX 2021003764 A MX2021003764 A MX 2021003764A MX 2021003764 A MX2021003764 A MX 2021003764A MX 2021003764 A MX2021003764 A MX 2021003764A MX 2021003764 A MX2021003764 A MX 2021003764A
Authority
MX
Mexico
Prior art keywords
fibromyalgia
bladder
gut
diagnosis
treatment
Prior art date
Application number
MX2021003764A
Other languages
English (en)
Inventor
Christopher Chang
Mark Pimentel
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of MX2021003764A publication Critical patent/MX2021003764A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Abstract

Se describen en la presente métodos y sistemas para la detección de anticuerpos antivinculina con el fin de determinar la presencia o posible presencia de un trastorno de la motilidad gastrointestinal, trastorno de la motilidad de la vejiga o fibromialgia. Además, se proporcionan métodos para seleccionar y/o administrar una terapia que se basa en la presencia o ausencia de anticuerpos antivinculina.
MX2021003764A 2012-09-17 2015-03-13 Determinacion de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia. MX2021003764A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261701923P 2012-09-17 2012-09-17
US201361762632P 2013-02-08 2013-02-08

Publications (1)

Publication Number Publication Date
MX2021003764A true MX2021003764A (es) 2021-05-27

Family

ID=50278832

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003326A MX2015003326A (es) 2012-09-17 2013-08-19 Diagnostico y tratamiento de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia.
MX2021003764A MX2021003764A (es) 2012-09-17 2015-03-13 Determinacion de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015003326A MX2015003326A (es) 2012-09-17 2013-08-19 Diagnostico y tratamiento de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia.

Country Status (10)

Country Link
US (4) US9702884B2 (es)
EP (1) EP2895856B1 (es)
KR (1) KR102203568B1 (es)
AU (1) AU2013315981B2 (es)
CA (1) CA2884413C (es)
DK (1) DK2895856T3 (es)
ES (1) ES2646598T3 (es)
HK (1) HK1207420A1 (es)
MX (2) MX2015003326A (es)
WO (1) WO2014042828A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
ES2646598T3 (es) 2012-09-17 2017-12-14 Cedars-Sinai Medical Center Diagnóstico y tratamiento de los trastornos de la motilidad del intestino y la vejiga, y de la fibromialgia
RU2683781C2 (ru) * 2013-10-09 2019-04-02 Седарс-Синаи Медикал Сентер Диагностика и лечение синдрома раздраженного кишечника и воспалительного заболевания кишечника
JP6784669B2 (ja) * 2014-10-09 2020-11-11 シーダーズ−サイナイ メディカル センター 炎症性腸疾患及びセリアック病から過敏性腸症候群を識別するための方法及びシステム
US11040083B2 (en) * 2015-09-29 2021-06-22 Paris Sciences Et Lettres—Quarter Latin Polypeptides comprising vinculin binding sites for the treatment of proliferation and/or adhesion related diseases
EP3573650A4 (en) * 2017-01-30 2020-12-09 Cedars-Sinai Medical Center DIAGNOSIS OF SCLERODERMIA
CN114895025A (zh) * 2021-07-01 2022-08-12 浙江大学 一种检测抗粘着斑蛋白-IgG抗体的试剂盒

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3425441B2 (ja) 1990-10-22 2003-07-14 ガストロ サービシイズ ピーティーワイ リミテッド 非炎症性及び非感染性腸障害の処置
US5691151A (en) 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
AU2007201246B2 (en) 2001-04-17 2008-12-04 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20030157159A1 (en) 2002-01-15 2003-08-21 Franklin Lanny Udell Prevention and treatment of digestive tract infections
AU2003233576A1 (en) 2002-05-17 2003-12-02 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
WO2004019907A1 (en) 2002-08-29 2004-03-11 Activbiotics, Inc. Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
CA2498274A1 (en) 2002-09-16 2004-03-25 Genentech, Inc. Compositions and methods for the diagnosis of immune related diseases using pro7
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
EP1664796B1 (en) 2003-09-15 2010-12-15 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate ankylosing spondylitis
CN1914322B (zh) 2003-12-05 2012-05-30 扶桑药品工业株式会社 细胞致死肿胀毒素及以其为目标的弯曲杆菌属细菌的检测
US20090233888A1 (en) 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
ES2538478T3 (es) 2006-08-02 2015-06-22 Salix Pharmaceuticals, Inc. Métodos para el tratamiento de enteritis por radiación
WO2008140484A2 (en) 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
DK2223121T3 (da) 2007-12-20 2012-10-22 Index Diagnostics Ab Publ Fremgangsmåde og kit til anvendelse ved differentiering mellem ibd og ibs og yderligere skelnen mellem ibd-sygdomstyper
MX2010009197A (es) 2008-02-26 2010-11-22 Salix Pharmaceuticals Ltd Metodos para tratar padecimientos del intestino.
GB2460717A (en) 2008-06-11 2009-12-16 Sense Proteomic Ltd Autoantibodies for the detection of a predisposition to Lupus
WO2010060098A1 (en) 2008-11-24 2010-05-27 Cedars-Sinai Medical Center Antioxidant camptothecin derivatives and antioxidant antineoplastic nanospheres thereof
CA2752033C (en) 2009-02-11 2020-03-24 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of campylobacter jejuni
CA2752020A1 (en) 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
FR2942541A1 (fr) * 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
ES2646598T3 (es) 2012-09-17 2017-12-14 Cedars-Sinai Medical Center Diagnóstico y tratamiento de los trastornos de la motilidad del intestino y la vejiga, y de la fibromialgia
RU2683781C2 (ru) 2013-10-09 2019-04-02 Седарс-Синаи Медикал Сентер Диагностика и лечение синдрома раздраженного кишечника и воспалительного заболевания кишечника
JP6784669B2 (ja) 2014-10-09 2020-11-11 シーダーズ−サイナイ メディカル センター 炎症性腸疾患及びセリアック病から過敏性腸症候群を識別するための方法及びシステム
EP3573650A4 (en) 2017-01-30 2020-12-09 Cedars-Sinai Medical Center DIAGNOSIS OF SCLERODERMIA

Also Published As

Publication number Publication date
US20180364255A1 (en) 2018-12-20
US9702884B2 (en) 2017-07-11
AU2013315981B2 (en) 2019-04-18
EP2895856A2 (en) 2015-07-22
ES2646598T3 (es) 2017-12-14
KR20150058404A (ko) 2015-05-28
CA2884413C (en) 2022-11-01
US9952223B2 (en) 2018-04-24
EP2895856A4 (en) 2016-06-08
US20180088130A1 (en) 2018-03-29
AU2013315981A1 (en) 2015-03-26
EP2895856B1 (en) 2017-10-04
DK2895856T3 (da) 2017-11-20
KR102203568B1 (ko) 2021-01-15
US20200271665A1 (en) 2020-08-27
WO2014042828A3 (en) 2014-10-16
MX2015003326A (es) 2015-08-12
US10466254B2 (en) 2019-11-05
US20150233944A1 (en) 2015-08-20
CA2884413A1 (en) 2014-03-20
WO2014042828A2 (en) 2014-03-20
HK1207420A1 (en) 2016-01-29

Similar Documents

Publication Publication Date Title
MX2021003764A (es) Determinacion de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia.
EA201792642A1 (ru) Способы диагностики для т-клеточной терапии
HK1244847A1 (zh) 用於膀胱癌症的治療，診斷和預後方法
HUE056315T2 (hu) A tumor molekuláris detektálására/diagnosztikájára szolgáló reagens
EP3156498A4 (en) Breast cancer detection kit or device, and method for detecting breast cancer
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
PH12014501844B1 (en) Peptidomimetic macrocycles
AP2016009549A0 (en) Methods for increasing red blood cell levels and treating sickle-cell disease
EA201691314A1 (ru) Терапевтические способы и композиции
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
GB201908185D0 (en) Reductant concentration diagnostic system and methods
DK2900279T3 (da) Grpr-antagonister til detektering, diagnose og behandling af grpr-positiv cancer
MX2016004167A (es) Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal.
MX2020007771A (es) Metodos para la supervision de la deteccion y el tratamiento de cancer de colon.
MX2016003674A (es) Matrices detectables, sistemas para el diagnostico y sus metodos de preparacion y uso.
EP3385717A3 (en) Methods of detecting prostate cancer
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
EP3693742A3 (en) Methods of detecting prostate cancer
MX2013010999A (es) Metodos de diagnostico y tratamiento utilizando una genoteca de ligandos.
WO2012019132A3 (en) Anaplastic lymphoma kinase in kidney cancer
CY1122474T1 (el) Μεθοδος διαγνωσης νευραλγιας του τριδυμου
WO2016133449A9 (en) Detection and treatment of malignant tumours in the cns
MX2015010776A (es) Metodos y composiciones para detectar y tratar mutantes de akt resistentes a farmacos.